Publication Name	World Journal of Gastroenterology
Manuscript ID	45018
Country	United Kingdom

Received	2018-12-07 06:09
Peer-Review Started	2018-12-09 13:11
First Decision by Editorial Office Director	2019-01-11 04:18
Return for Revision	2019-01-14 02:49
Revised	2019-01-17 10:01
Publication Fee Transferred
Second Decision by Editor	2019-01-25 10:04
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2019-01-26 05:34
Articles in Press	2019-01-26 05:34
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-02-26 07:41
Publish the Manuscript Online	2019-02-27 04:11

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Current and future pharmacological therapies for managing cirrhosis and its complications
Manuscript Source	Unsolicited Manuscript
All Author List	David Kockerling, Rooshi Nathwani, Roberta Forlano, Pinelopi Manousou, Benjamin H Mullish and Ameet Dhar
Funding Agency and Grant Number	Funding Agency Grant Number NIHR MRC MR/R00875/1 EASL
Corresponding Author	Ameet Dhar, BSc, MBBS, MRCP, PhD, Attending Doctor, Liver Unit/Division of Integrative Systems Medicine and Digestive Disease, Imperial College London, 10th Floor, QEQM Wing, St Mary’s Hospital Campus, South Wharf Road, Paddington, London W2 1NY, United Kingdom. a.dhar@imperial.ac.uk
Key Words	Cirrhosis; Beta-blockers; Rifaximin; Diuretics; Statins; Proton pump inhibitors; Pharmacology
Core Tip	Pharmacological therapy is central to the management of cirrhosis and its complications. Whilst there has been recent debate about the safety of beta-blockade in patients with ascites, conversely there is growing interest in potential benefits relating to a reduction in gut bacterial translocation and hepatocellular carcinoma risk. In addition to its well-established role in treating hepatic encephalopathy, rifaximin may also have a key role in preventing secondary infections. In this review, we summarise these and other uncertainties, controversies and novel developments related to pharmacotherapy in the clinical management of chronic liver disease.
Publish Date	2019-02-27 04:11
Citation	Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908
URL	https://www.wjgnet.com/1007-9327/full/v25/i8/888.htm
DOI	https://dx.doi.org/10.3748/wjg.v25.i8.888

Full Article (PDF)	WJG-25-888.pdf
Full Article (Word)	WJG-25-888.docx
Manuscript File	45018-Review.docx
Answering Reviewers	45018-Answering reviewers.pdf
Audio Core Tip	45018-Audio core tip.wav
Conflict-of-Interest Disclosure Form	45018-Conflict-of-interest statement.pdf
Copyright License Agreement	45018-Copyright license agreement.pdf
Peer-review Report	45018-Peer-review(s).pdf
Scientific Misconduct Check	45018-Scientific misconduct check.pdf
Scientific Editor Work List	45018-Scientific editor work list.pdf